PAHO Expands Access to HIV Prevention Drug

PAHO expands access to HIV prevention drug

WASHINGTON (CMC): The Pan American Health Organization (PAHO) says it is opening new avenues for countries in Latin America and the Caribbean (LAC) to access lenacapavir, a long-acting HIV prevention medicine aimed at curbing new infections across the region. Under an agreement with Gilead Sciences, the drug will be made available through PAHO’s Regional Revolving Funds, allowing 14 countries to procure the treatment.

Dr Reddy’s inks licensing deal with Gilead for once-yearly HIV lenacapavir

Dr Reddy’s signs royalty-free, non-exclusive voluntary licence with Gilead for investigational once-yearly lenacapavir PrEP in 120 high-incidence countries.

Dr. Reddy’s expands Gilead pact for HIV prevention drug

Dr. Reddy’s Laboratories has entered into a royalty-free non-exclusive voluntary licensing agreement with Gilead Sciences for investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP).

Gilead expands voluntary licensing agreements for once-yearly Yeztugo (GILD:NASDAQ)

Gilead adds once-yearly Yeztugo (lenacapavir) HIV PrEP to royalty-free licenses across 120 countries. Read more here.

Dr. Reddy's expands collaboration with Gilead Sciences for investigational once-yearly lenacapavir for HIV prevention

Dr. Reddy’s Laboratories announced a royalty-free non-exclusive voluntary licensing agreement with Gilead Sciences for investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP). The agreement builds on Dr. Reddy’s existing voluntary licensing arrangement with Gilead, signed in October 2024, for twice-yearly lenacapavir for HIV prevention and treatment and reflects the continued confidence between the […]